Letter to Editor

An agonist of the CXCR4 receptor is therapeutic for the neuroparalysis induced by Bungarus snakes envenoming

Dear Editor,

Here, we report the therapeutic properties of a small molecule agonist of the CXCR4 receptor on the recovery from the peripheral flaccid neuroparalysis caused by Bungarus snakebites. Snake envenoming is a neglected disease that, each year, causes >100,000 deaths in tropical and subtropical areas of the world and leaves >400,000 envenomed patients with permanent disabilities, with associated high social costs (https://www.who.int/news-room/fact-sheets/detail/snakebite-envenoming). This is a disease of poverty believed by experts to be under reported. Moreover, snake envenoming strikes particularly in lower income and rural parts of the world where advanced hospital care may not be rapidly available to the envenomed patient.

A major number of neuropathological snakebites are produced by snakes of the Bungarus genus widely distributed in Asia. Their venoms induce a descending flaccid paralysis with respiratory failure and autonomic dysfunctions. A large reduction of the function of the neuromuscular junction (NMJ) can be recorded electrophysiologically within few hours from snakebite, and death may occur by respiratory failure. Mechanically ventilated patients survive because the Bungarus neurotoxins do not kill motor neurons but induce a rapid degeneration limited to the axon terminals which is followed by a slow regeneration requiring prolonged hospitalization (3–5 weeks) and eventual recovery. However, hospitalization with mechanical ventilation poses major problems in low-income countries associated with high costs and risks of in-hospital complications.

The pathophysiology of Bungarus snake envenoming is primarily driven by neurotoxicity caused by protein neurotoxins. The presynaptically acting β-bungarotoxins (β-BTX) are phospholipases A2 that cleave the ester bond of the fatty acid in the sn-2 site of the glycerol moiety of phospholipids, causing accumulation of fatty acids and lysophospholipids leading to rapid degeneration of axon terminals within few hours in mice. This is followed by regrowth of the motor axon terminal with restoration of a functional NMJ. This remarkable process is almost complete within about a week in young mice and can be monitored by imaging the NMJ using presynaptic protein markers and by electrophysiology.

Recently we discovered that the degeneration of the motor axon terminal is accompanied by the expression of the CXCR4 receptor on the neuronal plasma membrane and that a small molecule CXCR4 agonist, dubbed NUCC-390, promotes the recovery of function of the NMJ degenerated by the spider α-latrotoxin. Therefore, we investigated the utility of NUCC-390 in treating neurotoxicity induced by the venoms of three most common Asiatic krait species, that is, Bungarus caeruleus, Bungarus candidus and Bungarus multicinctus.

Figure 1 and Figure S1 show that the venoms cause a rapid and complete degeneration of the motor axon terminals leaving intact the convoluted post-synaptic structure of the NMJ. This is accompanied by the surface expression of the CXCR4 receptor (Figure 1 Supp video), and the CXCR4 staining is concentrated on nerve axon stumps close to perisynaptic Schwann cells (Figure S2). CXCR4 persists for a long time period, to decline by day 7, when recovery of the NMJ is accomplished. Figure 1 also shows that this phenomenon is due to β-BTX and not to α-BTX which is a post-synaptic neurotoxin present in some of the Bungarus venoms. These findings provide the basis for testing the effect of the CXCR4 receptor agonist NUCC-390 on NMJ anatomical and functional regeneration.

Functional recovery of the NMJ was quantitatively assessed by electrophysiology performed on single muscle fibres (evoked junctional potential) or on the muscle (compound muscle action potential [CMAP]). Figure 2 shows that NUCC-390 accelerates the recovery of NMJ function from the neuroparalysis caused by three different Bungarus venoms or β-BTX. Figure 2D shows that the NUCC-390 effect is mediated by its action on the CXCR4 receptor as it is completely prevented by the very specific antagonist AMD3100. This finding on single
FIGURE 1  CXCR4 receptor expression on mouse neuronal axons after i.m. injection of Bungarus caeruleus venom, β- and α-bungarotoxins. 36 ng/g B. caeruleus venom (2nd, 3rd and 4th rows), 1 ng/g of β-bungarotoxin (5th, 6th and 7th rows) and 1 ng/g of α-bungarotoxin (bottom row) were injected i.m. in the hind limb of young mice, and the soleus muscle was dissected and stained with antibodies specific for the following antigens. Left set of panels: first column: vesicle-associated membrane protein isoform-1 (VAMP-1), a marker of motor axon terminals; second column: nicotinic acetyl choline receptor (nAChR), a marker of the post-synaptic muscle membrane, was stained with fluorescent alpha-bungarotoxin; third column: merging with the staining obtained with an anti-neurofilaments (chicken polyclonal, Abcam, cat# Ab4680) in grey. The right set of panels shows samples of soleus muscle, poisoned as above, stained with: first column: anti CXCR4 receptor (rabbit monoclonal, Abcam, cat# Ab124824) (red); second column: anti-neurofilaments (NF, green), third column, merging with Schwann cells expressing GFP (light blue) showing that the CXCR4 staining is concentrated on nerve axon stumps close to the perisynaptic Schwann cells. Symbols of the rows: Samples taken from non-injected control muscles (ctr), or venom treated muscles after 24 h, 96 h and 168 h from i.m. injection of Bungarus caeruleus venom in the hind limb. Notice that the degeneration of the motor axon terminal at the neuromuscular junction with time is complete after 24 h from poisoning as shown by the loss of VAMP-1 staining. Degeneration is accompanied by the expression of the CXCR4 receptor on the remaining motor axon, and this receptor is still present 4 days after poisoning. A lower magnification was used (scale bar 50 μm) in most panels to provide a view of several neuromuscular junctions in the same field, whilst a higher one (scale bar 20 μm) was used in other panels to better show the expression of the CXCR4 receptor.
NUCC-390 promotes the recovery of evoked junction potentials (EJPs) of neuromuscular junctions of single muscle fibres of the mouse soleus muscles injected with the venoms of *Bungarus caeruleus*, *Bungarus candidus* or *Bungarus multicinctus* or β-bungarotoxin. (A) Schematic representation of the technique of measurement of the evoked junctional potentials (EJPs) by insertion of the recording electrode inside the muscle fibre. (B) Timeline scheme of the injections of toxin or venoms (quantities as in Figure 1) and of NUCC-390 administration (3.2 mg/Kg in 20-μl physiological solution containing 2% gelatine per day) or vehicle only or with additional i.p. injection of 100 μg AMD3100 (in 40-μl physiological solution containing 0.2% gelatine, prior to NUCC-390 injection). (C) Chemical formula of CXCR4 agonist dubbed NUCC-390. (D) EJPs of soleus muscles 96-h post injection of β-bungarotoxin in the hind limb of mice daily treated with NUCC-390 (blue column) or vehicle (grey column) or NUCC-390 plus the CXCR4 antagonist AMD3100 (striped column). Each bar represents the mean of the EJP amplitude ± SEM from *N* = 5 soleus muscles, number of analysed fibres for each muscle: 12, **p = .0077. (E, F and G) EJPs of soleus muscles 96 h after the injection of the indicated snake venoms in the hind limb of mice treated (blue columns) or not treated (grey columns) daily with NUCC-390. Each bar represents the mean of the EJP amplitude ± SEM from *N* = 5, number of analysed fibres: 12, (E) **p = .0099, (F) *p = .0193, (G) **p = .0019
FIGURE 3  Accelerated recovery of compound muscle action potential from the paralysis caused by *Bungarus* venoms induced by NUCC-390. (A) Compound muscle action potential (CMAP) values recorded on gastrocnemius muscles 96 h after mock treatment or injection with *B. caeruleus*, *B. candidus*, or *B. multicinctus* venoms, w/o NUCC-390 daily local administration, using concentration as in Figure 2. The venom affects all the muscles around the site of the injection in mice. Data are expressed as CMAP amplitude (mV) ± SEM. *(B. caeruleus) **p = .0049, (B. candidus) **p = .0028, (B. multicinctus) **p = .005. **p < .01.* (B) Representative immunostaining of intoxicated neuromuscular junctions (NMJs), performed on the same muscles used for CMAP analysis. Motor neurons axon terminals are identified by vesicle-associated membrane protein isoform-1 (VAMP-1) immunostaining (green), post-synaptic nicotinic acetyl choline receptors (nAChRs) by fluorescent α-BTX (red) and the axon by neurofilaments (NF) staining (chicken polyclonal, Abcam, cat# Ab4680) (white). Scale bars: 50 μm

As *Bungarus* envenoming results in deficit of lung ventilation, NUCC-390 was tested on the recovery of the respiratory function in envenomed mice using a very sensitive and minimally invasive test. A probe connected to a pressure sensor was placed inside the esophagus at the mediastinum level in anesthetized mice. Figure 4 shows the recorded signal characterized by asymmetric peaks with a frequency corresponding to events of lung ventilation. The peak area provides an estimate of the volume of air inspired which results from the activity of respiratory muscles. *Bungarus* venoms decrease both frequency and extent of ventilation with changes in shape and dimension of each peak (Figure 4A). NUCC-390-treated
animals showed an increase in peak area compared to untreated mice after 24 h, and this effect amplified with time. At 96 h, NUCC-390-treated mice showed a complete recovery in lung ventilation, a result reached by control animals only after 1 week. A quantitative analysis shows that, after the initial decline due to envenomation (4-h point in the graph of panel C of Figure 4), NUCC-390 accelerates the recovery of ventilation after envenomation (panel B) as compared to controls. This functional recovery is accompanied by the restoration of the structure of diaphragm NMJs as shown in Figure 4D.

Taken together, the data presented here qualify NUCC-390 as a novel potential therapeutic to accelerate nerve structural and functional recovery from the neurodegeneration and paralysis caused by Bungarus snake envenoming. The molecule is stable, non-toxic, of simple chemical synthesis and does not suffer from the limitations of anti-venom antisera because its efficacy does not depend on the species specificity and origin of the antiserum and can be administered also even days after snakebite. In fact, NUCC-390 is complementary to antiserum because of its different mechanism of action which leads to a more rapid recovery from a peripheral neuroparalysis, thereby shortening the mechanical ventilation period with a parallel decrease of healthcare costs. This is important particularly in developing countries where most of neuroparalytic snakebites occur. These properties and considerations support the proposal of a rapid translation of NUCC-390 to trials in envenomed patients.
This work was supported by the funding from the University of Padova and by the project “RIPANE” of the Italian Ministry of Defense. We would like to thank Dr. M. Pirazzini for critical reading the manuscript.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

REFERENCES
1. Williams D, Gutiérrez JM, Harrison R, Warrell DA, White J, Winkel KD, Gopalakrishnakone P. The Global Snake Bite Initiative: an antidote for snake bite. The Lancet. 2010;375:(9708):89–91. http://doi.org/10.1016/s0140-6736(09)61159-4
2. Ranawaka UK, Lalloo DG, de Silva HJ. Neurotoxicity in snakebite – the limits of our knowledge. PLoS Negl Trop Dis. 2013;7:e2302.
3. Silva A, Maduwaage K, Sedgwick M, et al. Neuromuscular Effects of common krait (Bungarus caeruleus) envenoming in Sri Lanka. PLoS Negl Trop Dis. 2016;10:e0004368.
4. Rigoni M, Caccin P, Gschmeissner S, et al. Equivalent effects of snake PLA2 neurotoxins and lysophospholipid-fatty acid mixtures. Science. 2005;310:1678-1680.
5. Negro S, Lessi F, Duregotti E, et al. CXCL12α/SDF-1 from perisynaptic Schwann cells promotes regeneration of injured motor axon terminals. EMBO Mol Med. 2017;9:1000-1010.
6. Mishra RK, Shum AK, Platianis LC, Miller RJ, Schiltz GE. Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists. Sci Rep. 2016;6:30155.
7. Mishra RK, Shum AK, Platianis LC, Miller RJ, Schiltz GE. Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists. Sci Rep. 2016;6:30155.
8. Tan NH, Tan KY, Tan CH. Snakebite in Southeast Asia: envenoming and clinical management. Handbook of Venoms and Toxins of Reptiles. 2nd ed. CRC Press: 2021.
9. Gutiérrez JM, Warrell DA, Williams DJ, et al. The need for full integration of snakebite envenoming within a global strategy to combat the neglected tropical diseases: the way forward. PLoS Negl Trop Dis. 2013;7:2162.
10. Gutiérrez JM, Albulescu LO, Clare RH, et al. The search for natural and synthetic inhibitors that would complement antivenoms as therapeutics for snakebite envenoming. Toxins (Basel). 2021;13:E451.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.